ArticleJournal of hepatocellular carcinoma2026
Etiology Dependent Differences in Immunotherapy Response and Prognosis Between MASH-HCC and HBV-HCC.
Article in Journal of hepatocellular carcinoma, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The incidence of metabolic dysfunction-associated steatohepatitis related hepatocellular carcinoma is increasing. However, its response to immunotherapy remains unclear. This study aimed to compare the prognosis of patients with MASH-HCC and hepatitis B virus-related HCC (HBV-HCC) under different treatment strategies. Methods: This single-center retrospective study included 218 patients with HCC from 2022 to 2025. The primary endpoint was progression-free survival (PFS), and the secondary endpoint was 1-year overall survival (OS). Kaplan-Meier analysis, Cox regression models, and restricted cubic spline (RCS) analysis were used to evaluate the association between immune cells and prognosis. Stratified and subgroup analyses were also performed. Results: A total of 136 HBV-HCC and 82 MASH-HCC patients were enrolled in this study. PFS was significantly longer in HBV-HCC patients than in MASH-HCC patients (70.59% vs 41.46%, Conclusion: MASH-HCC patients showed a trend toward poorer response to ICI therapy compared with HBV-HCC patients, particularly in those with CD4⁺ T cell counts <354 cells/μL. These results suggest that both disease etiology and immune status may contribute to variability in immunotherapy outcomes and warrant consideration in treatment decision making.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.